548 related articles for article (PubMed ID: 26834067)
1. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
Brown KT; Do RK; Gonen M; Covey AM; Getrajdman GI; Sofocleous CT; Jarnagin WR; D'Angelica MI; Allen PJ; Erinjeri JP; Brody LA; O'Neill GP; Johnson KN; Garcia AR; Beattie C; Zhao B; Solomon SB; Schwartz LH; DeMatteo R; Abou-Alfa GK
J Clin Oncol; 2016 Jun; 34(17):2046-53. PubMed ID: 26834067
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
3. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
[TBL] [Abstract][Full Text] [Related]
5. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
6. The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation study.
Klass D; Owen D; Buczkowski A; Chung SW; Scudamore CH; Weiss AA; Yoshida EM; Ford JA; Ho S; Liu DM
Anticancer Res; 2014 Jul; 34(7):3597-606. PubMed ID: 24982375
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
8. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
10. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
[TBL] [Abstract][Full Text] [Related]
11. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma.
Muros-Ortega M; Díaz-Carrasco MS; Capel A; Calleja MÁ; Martínez F
Int J Clin Pharm; 2013 Dec; 35(6):1105-12. PubMed ID: 23928684
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
Lokken RP; Fidelman N; Kolli KP; Kerlan RK
J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
[TBL] [Abstract][Full Text] [Related]
15. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.
Urbano J; Echevarria-Uraga JJ; Ciampi-Dopazo JJ; Sánchez-Corral JA; Cobos Alonso J; Anton-Ladislao A; Peña-Baranda B; Nacarino-Mejias V; González-Costero R; Muñoz Ruiz-Canela JJ; Pérez-Cuesta J; Lanciego C; de Gregorio MA
Eur J Radiol; 2020 May; 126():108966. PubMed ID: 32278280
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma.
Malagari K; Kiakidis T; Pomoni M; Moschouris H; Emmanouil E; Spiridopoulos T; Sotirchos V; Tandeles S; Koundouras D; Kelekis A; Filippiadis D; Charokopakis A; Bouma E; Chatziioannou A; Dourakis S; Koskinas J; Karampelas T; Tamvakopoulos K; Kelekis N; Kelekis D
Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1379-91. PubMed ID: 27393274
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Very Small Drug-Eluting Beads Used in Chemoembolization of Unresectable Hepatocellular Carcinoma.
Aal AKA; Moawad S; Lune PV; El Khudari H; Hanaoka MM; Abouldahab N; Gunn AJ; White J; Shoreibah M; Li Y; Saddekni S; Mahmoud K
J Vasc Interv Radiol; 2019 Sep; 30(9):1325-1334.e2. PubMed ID: 31371139
[TBL] [Abstract][Full Text] [Related]
18. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
[TBL] [Abstract][Full Text] [Related]
19. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Aliberti C; Carandina R; Sarti D; Mulazzani L; Pizzirani E; Guadagni S; Fiorentini G
AJR Am J Roentgenol; 2017 Aug; 209(2):430-434. PubMed ID: 28537756
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
